Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and how well of pembrolizumab and a vaccine
therapy (ATL-DC vaccine) work in treating patients with glioblastoma that has come back
(recurrent) and can be removed by surgery (surgically accessible). Immunotherapy with
monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Vaccines, such
as ATL-DC vaccine, may help the body build an effective immune response to kill tumor cells.
Giving pembrolizumab and ATL-DC vaccine may work better in treating patients with
glioblastoma compared to ATL-DC alone.
Phase:
Phase 1
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI) Oncovir, Inc. Phase One Foundation